The short version of Lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The main SF unit in South Vietnam was the 5th Special Forces Group (Airborne). SF soldiers assigned to the 5th Group earned sixteen Medals of Honor in Vietnam, making it the most prominently decorated unit for its size in that conflict. The unit was also awarded the coveted Presidential Unit Citation for extraordinary heroism during the Vietnam War from 1 November 1966 – 31 January 1968. Army Special Forces personnel also played predominant roles in the highly secret, covert, multi-service Military Assistance Command Vietnam Studies and Observation Group (MACV-SOG), with an extraordinarily large number of covert U.S. military personnel killed or lost MIA while operating on Studies and Observations Group (SOG) reconnaissance missions in Laos and Cambodia. During the prolonged conflict the Army Special Forces trained regular and paramilitary units of several Allied nations as well as US reconnaissance members; supervised the indigenous Civilian Irregular Defense Group stationed throughout Vietnam in fortified camps and as backup reserves; monitored the border region and infiltration routes; conducted strategic intelligence missions and fielded numerous elements engaged in special operational tasks. From 1957 to 1973, over 20,000 Special Forces soldiers served out of a total of 3.2 million American servicemen, who were deployed throughout the war. Of these 882 died, killed in action or went missing in Southeast Asia (including 121 in Laos and 32 in Cambodia). The "Green Beret Affair": U. S.
== Rankings and selectivity == U.S. News & World Report ranked the School of Medicine 74th (2022–23) in the Best Research category and 90th (2022–23) in the Primary Care category nationally. In 2020, the MD program received over 6,100 applications for 182 seats. The incoming class had an average GPA of 3.75 and MCAT score of 512, which is the 85th percentile nationally. Over 87.4% matriculants were NYS residents, the remaining 12.6% were "out of state".
Fast CFDs of advanced designs have the dead times equal to or less than two single-hit response times of the ion detector (single-hit response time for MCP with 2-5 micron wide channels can be somewhere between 0.2 ns and 0.8 ns, depending on the channel angle) thus preventing repetitive triggering from the same pulse. Double-hit resolution (dead time) of modern multi-hit TDC can be as low as 3-5 nanosecond. The TDC is a counting detector – it can be extremely fast (down to a few picosecond resolution), but its dynamic range is limited due to its inability to properly count the events when more than one ion simultaneously (i.e., within the TDC dead time) hit the detector. The outcome of limited dynamic range is that the number of ions (events) recorded in one mass spectrum is smaller compared to real number. The problem of limited dynamic range can be alleviated using multichannel detector design: an array of mini-anodes attached to a common MCP stack and multiple CFD/TDC, where each CFD/TDC records signals from individual mini-anode. To obtain peaks with statistically acceptable intensities, ion counting is accompanied by summing of hundreds of individual mass spectra (so-called hystograming). To reach a very high counting rate (limited only by duration of individual TOF spectrum which can be as high as few milliseconds in multipath TOF setups), a very high repetition rate of ion extractions to the TOF tube is used. Commercial orthogonal acceleration TOF mass analyzers typically operate at 5–20 kHz repetition rates.
Meats, poultry and fish all must be kept in climate-controlled environments before being sold. Refrigeration also helps keep fruits and vegetables edible longer. One of the most influential uses of refrigeration was in the development of the sushi/sashimi industry in Japan. Before the discovery of refrigeration, many sushi connoisseurs were at risk of contracting diseases. The dangers of unrefrigerated sashimi were not brought to light for decades due to the lack of research and healthcare distribution across rural Japan. Around mid-century, the Zojirushi corporation, based in Kyoto, made breakthroughs in refrigerator designs, making refrigerators cheaper and more accessible for restaurant proprietors and the general public.
Sources: en.wikipedia.org
Ultraviolet radiation is helpful in the treatment of skin conditions such as psoriasis and vitiligo. Exposure to UVA, while the skin is hyper-photosensitive, by taking psoralens is an effective treatment for psoriasis. Due to the potential of psoralens to cause damage to the liver, PUVA therapy may be used only a limited number of times over a patient's lifetime. UVB phototherapy does not require additional medications or topical preparations for the therapeutic benefit; only the exposure is needed. However, phototherapy can be effective when used in conjunction with certain topical treatments such as anthralin, coal tar, and vitamin A and D derivatives, or systemic treatments such as methotrexate and Soriatane.
Intentional: buried alive as a method of execution or murder, called immurement when the person is entombed within walls. In ancient Rome, Vestal Virgins who broke their vows were punished in this way. Accidental: A person or group of people in a cave, mine, or other underground area may be sealed underground by an earthquake, cave in, avalanche or other natural disaster or accident. Inadvertent: People have been buried alive because they were mistakenly pronounced dead by a coroner or other official. Edgar Allan Poe wrote a number of stories and poems about premature burial, including a story called "The Premature Burial". These works inspired a widespread popular fear of this appalling but unlikely event. Various expedients have been devised to prevent it, including burying telephones or sensors in graves.
HbA1c of less than 7.0% if they are achievable without significant hypoglycemia Preprandial (before eating) blood glucose: 70 to 130 mg/dL (3.9 to 7.2 mmol/L) 2-hour postprandial (after eating) blood glucose: Less than 180 mg/dL (<10 mmol/L) Goals should be individualized based on:
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.